First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors.
Mark YarchoanJohn D PowderlyBruno R BastosThomas Benjamin KarasicOxana V CryslerPamela N MunsterMeredith A McKeanLeisha A EmensYvonne M SaengerYasser GedRobert StaggSteven SmithChan C WhitingAnne MoonPeppi PrasitYonchu JenkinsNathan StandiferThomas W DubenskySam H WhitingSusanna V UlahannanPublished in: Cancer research communications (2024)
TPST-1120 is a first-in-class oral inhibitor of PPARα, whose roles in metabolic and immune regulation are implicated in tumor proliferation/survival and inhibition of anticancer immunity. This first-in-human study of TPST-1120 alone and in combination with nivolumab supports proof-of-concept of PPARα inhibition as a target of therapeutic intervention in solid tumors.